ROG has been the subject of several other reports. Societe Generale set a CHF 190 price objective on shares of Roche and gave the stock a sell rating in a research report on Monday, January 15th. Goldman Sachs set a CHF 300 price objective on shares of Roche and gave the stock a buy rating in a research report on Tuesday, March 20th. JPMorgan Chase & Co. set a CHF 300 price objective on shares of Roche and gave the stock a buy rating in a research report on Thursday, January 4th. Barclays set a CHF 305 price objective on shares of Roche and gave the stock a buy rating in a research report on Thursday, December 21st. Finally, Nord/LB restated a buy rating on shares of Roche in a research report on Wednesday, December 27th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of CHF 254.80.
Shares of Roche (VTX ROG) opened at CHF 219.60 on Friday. The stock has a market cap of $191,160.00 and a PE ratio of 21.87. Roche has a one year low of CHF 214.30 and a one year high of CHF 273.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.